Related Experiment Video
Updated: Aug 5, 2025

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
Published on: March 17, 2023
Thyrotoxic hypokalemic periodic paralysis and COVID-19 infection
Sitanun Chinangkulpiwat1,2, Jutamart Tantiprawan2, Jakkrit Amornvit2
1Department of Medicine, Bang Phli Hospital, Samut Prakan Province, Bangkok, Thailand.
Abstract:
Various conditions causing weakness associated with coronavirus disease 2019 (COVID-19) infection have been described, including cerebrovascular diseases, acute myelitis, Guillain-Barré syndrome, myasthenia gravis, critical illness myopathy and neuropathy, myositis, and rhabdomyolysis. We report an adult man presenting with an unusual etiology of weakness after a COVID-19 infection. Thyrotoxic hypokalemic periodic paralysis (THPP) was diagnosed from the presence of Graves' disease and hypokalemia because of intra-cellular potassium shifting. His weakness and hypokalemia responded well to potassium supplements and a non-selective b-blocker, whereas his thyrotoxicosis was initially controlled by an anti-thyroid medication and subsequently with radioactive iodine therapy. He was also treated as having mild COVID-19 based on his normal chest X-ray and oxygenation level. This is the first report showing an association between COVID-19 infection and a paralysis attack of THPP. Physicians should be alerted about this unusual cause of weakness, particularly in Asian patients.
More Related Videos
Related Concept Videos
Myocarditis III: Medical Management
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis I: Introduction
Dysrhythmias II: Classification of Tachyarrhythmias
Pericarditis II: Clinical Features and Diagnostic Tests
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

